Abstract
SpCas9 and AsCas12a are widely utilized as genome editing tools in human cells, but their applications are largely limited by their bulky size. Recently, AsCas12f1 protein, with a small size (422 amino acids), has been demonstrated to be capable of cleaving double-stranded DNA protospacer adjacent motif (PAM). However, low editing efficiency and large differences in activity against different genomic loci have been a limitation in its application. Here, we show that engineered AsCas12f1 sgRNA has significantly improved the editing efficiency in human cells and mouse embryos. Moreover, we successfully generated three stable mouse mutant disease models using the engineered CRISPR-AsCas12f1 system in this study. Collectively, our work uncovers the engineered AsCas12f1 system expands mini CRISPR toolbox, providing a remarkable promise for therapeutic applications.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Programmable clustered regularly interspaced short palindromic repeats (CRISPR) associated Cas12f endonucleases, also known as Cas14 [1,2,3]. Cas12f effector proteins, the single-stranded DNA (ssDNA)-specific nucleases, have exhibited abilities to cleave double-stranded DNA (dsDNA) with 5′ T-rich or C-rich protospacer adjacent motifs (PAMs) [4,5,6]. Up to date, AsCas12f1 (422 aa) [5], Un1Cas12f1 (529 aa) [4, 7], SpaCas12f1 (497 aa) [8], RhCas12f1 (415 aa) [6], and OsCas12f1 (433 aa) [6] have been experimentally validated for programmed DNA cleavage in mammalian cells. However, compared with the well-characterized Cas9 and Cas12a complexes, the CRISPR-Cas12f systems are less potent in cleaving dsDNA and show larger activity variations when targeting different genomic loci [1, 2, 9,10,11]. Therefore, improving the editing efficiency of CRISPR-Cas12f systems becomes a key point for widespread applications.
The Cas12f from Acidibacillus sulfuroxidans (AsCas12f1), which consists of 422 amino acids, can cleave double-stranded DNA targets with a NTTR (where R represents A or G) PAM [2, 5]. Meanwhile, AsCas12f1 exhibits low but detectable genome editing activity in human cells [12,13,14]. By engineering the sgRNA, the naturally ineffective CRISPR-Un1Cas12f1 was turned into an efficient genome editing nuclease for mammalian genome regulation [7, 8]. Therefore, AsCas12f1 shows great promise as a miniature genome editing tool.
In this study, we took rational methods to engineer the AsCas12f1 sgRNA scaffold and obtained As-v1 variant. The results of deep sequencing showed that the engineered AsCas12f1 system generated 3.17-fold more efficiently than the wild type (WT) in the human genome. In addition, we tested genome editing in mouse embryos using the optimized version, and successfully generated mouse disease models. Together, the engineered AsCas12f1 system enables robust and faithful gene editing in mammalians.
Materials and methods
Animals
All mice mentioned were obtained from the Laboratory Animal Center of Jilin University (Changchun, China). All animal studies were conducted according to experimental practices and standards approved by the Animal Welfare and Research Ethics Committee at Jilin University (SY202302001).
Plasmid construction
The pCMV-AsCas12f1 plasmid was a kind gift from Quanjiang Ji. All the sgRNA scaffold fragments were synthesized and cloned into pCMV-AsCas12f1 plasmid by Genscript Biotech (Nanjing, China). The Un1Cas12f1 plasmid was obtained from Addgene (#176544).
Cell culture and transfection
HEK293T and N2a cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Meilun Biotechnology Co., Ltd) supplemented with 10% fetal bovine serum (HyClone) and incubated at 37 °C with 5%CO2. The cells were seeded into six-well plates and transfected using Hieff Trans™ Liposomal Transfection Reagent (Yeasen, Shanghai, China) according to manufacturer’s instructions [15]. After 72 h of transfection, genomic DNA was collected and used for genotyping. The sequencing of sgRNA and the primers used for genotyping are listed in Table S1 and S2.
mRNA and gRNA preparation
The pCMV-AsCas12f1 was linearized with XbaI, and transcribed in vitro using the HiScribe™ T7 ARCA mRNA kit (NEB). The mRNA was purified using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol [16]. Cloning of an annealed complementary oligonucleotide pair into a BsaI digested gRNA expression vector (Table S2). The sgRNAs were transcripted using the MAXIscript T7 kit (Ambion) and purified using miRNeasy Mini Kit (Qiagen) in vitro.
Microinjection of mice zygotes
The protocol used for the microinjection of pronuclear-stage embryos has been described in detail in our previous study [16, 17]. In brief, a mixture of gRNAs (40 ng/μl) and AsCas12f1 (80 ng/μl) was injected into the cytoplasm of pronuclear-stage embryos. The injected mouse zygotes were cultured at 37 °C under 5% CO2 in air until the two-cell stage, after which approximately 30–50 injected zygotes were then transferred into the oviducts of the recipient mice.
Single-embryo PCR amplification and mouse genotyping
The single-embryo PCR amplification and mouse genotyping were performed according to our previous study [17]. All the primers for genotyping are listed in Table S2.
H&E staining
The skin from WT and KO mice were fixed with 4% paraformaldehyde for 48 h, embedded in paraffin wax, sectioned, mounted on slides, stained with H&E [18, 19] and imaged with a Nikon TS100 microscope.
Open-field test
The open-field test was used to assess the locomotor and exploratory activity of the mice when they were placed in an unfamiliar environment [20]. The open field was a (l × w × h, 60 cm × 30 cm × 15 cm) box with a non-reflective rectangle base. We defined the center area (30 cm × 15 cm) and the margin area (between the side and 80% of the bottom area, outside of 48 cm × 24 cm). For each testing session, a mouse was placed individually in the center of the arena and allowed to freely explore the environment for 7 min. Travel path were detected by Image J and Animal Tracker 5.6 software [20].
Novelty-suppressed feeding assay
It consisted of a square base (l × w: 60 cm × 30 cm) with a small pre-weighed food chow pellet (sweets) placed in the center of the arena on a small fixed dish. The mice were individually placed in a clean cage without food 24 h before testing. Feeding was defined as the mouse grabbing the pellet and starting to eat. The mouse was removed after 6 min. The latency for a mouse to approach and eat a new food in a novel environment following an extended period (16–24 h) of food deprivation was used as an index of anxiety-like behavior [21].
Off-target assay
The potential off-target sites for each target in mice were predicted using an online tool (http://www.rgenome.net/cas-offinder/) [22]. First, select PAM type according to specific CRISPR/Cas-derived RNA-guided endonucleases, including AsCas12f1 (PAM:NTTR, R = A or G); next, select the vertebrate genomes and the corresponding Mus musculus (mm10)—mouse genome; then write crRNA sequences without PAM sequences and select the mismatch number to get potential off-target sites. Finally, click submit. The genomic regions surrounding the off-target site were PCR amplified and then subjected to deep sequencing. Mutations were detected by Hi-TOM analysis (http://121.40.237.174/Hi-TOM/). Hi-TOM analysis is an online tool for high-throughput mutation tracking, which can accurately analyze the mutation percentage of each on- and off-target sites [23]. Off-target sites and primers used to amplify target sequences are listed in Table S3 and S4.
Statistical analysis
The indel editing efficiencies of AsCas12f1 were determined by deep sequencing. All data are expressed as mean ± s.d. (standard deviation), with at least three individual determinations in all experiments. The data were analyzed with t tests using Graphpad prism software 8.0.2. A probability of p < 0.05 was considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Engineered AsCas12f1-associated gRNA with elevated editing efficiency in HEK293T cells
To confirm the editing efficiency of WT CRISPR-AsCas12f1 system, 15 target sites with qualified PAMs were selected in HEK293T cells. The results of indels showed that AsCas12f1 generated low efficient editing, which was difficult to be a mammal genome editing tool (Fig. S1).
The sgRNA of AsCas12f1 is a fusion of a 49 nt CRISPR RNA (crRNA) and a 138 nt trans-activated CRISPR RNA (tracrRNA), consisting of 5 stem loops (Figs. 1b and S2) [5, 24]. Notably, AsCas12f1 sgRNA is much longer and adopts a similar structure with Un1Cas12f1 sgRNA (Fig. 1a, b) [5, 25, 26]. Modification of the 3′ poly-uridine (U) and 5`GGG overhanging on gRNAs have been shown to increase gRNA stability, and consequently improve Cas nuclease efficiency [7, 27, 28]. In this study, we separately fused 5′-TTTTATTTTTTT (T4AT6)-3′ and 5′-GGG-3′ sequence to sgRNAs (Fig. 1c). To test the endogenous editing activity, the four target sites (PDCD1/TP53/VEGFA/FGF18) were chose in HEK293T cells. The results showed that T4AT6 significantly improved the efficiency in four target sites compared with the original sgRNA, while GGG had no significant improvement at all locus (Fig. 1d). According to the gRNA engineering strategy for Un1Cas12f1 and SpaCas12f1, we designed schemes of MS (modify site throughout the tracrRNA and crRNA) and DS (delete site of stem 2 region in the tracrRNA) in Fig. 1. As shown in Figs. 1e, f and S3, the MS improved editing efficiency at all target sites ranging from 1.21- to 2.07-fold and significantly improved indels at the PDCD1 site. The DS1 and DS2a failed to yield higher editing efficiency at all sites. The DS2b reduced editing frequency at four sites compared with the WT, while it retained large part sequences of the stem-loop 2 (Fig. 1g, h). Then we combined T4AT6 and MS modifications mentioned above to form the new sgRNA version-As-v1 (Fig. 2a). Compared with other modification and WT sgRNA in HEK293T cell, As-v1 observed 3.17-fold more indels than WT sgRNA at PDCD1 loci, significantly improving the CRISPR-AsCas12f1 system indel activity (Figs. 2b and S3). In addition, we tested AsCas12f1 paired with As-v1 and Un1Cas12f1-ge4.1 across 12 genomic loci. The results showed that AsCas12f1 generated higher efficient editing at all target sites than UnCas12f1, ranging from 1.37- to 2.68-fold (Fig. 2c). Collectively, the AsCas12f1 paired with As-v1 (engineered AsCas12f1 system) significantly improved editing efficiency in mammalian cells. The As-v1 version of sgRNA was used for subsequent efficiency assessment in mice.
Different gRNA engineering schemes and their mediated indels in human HEK293T cells. a Size comparison (aa) of conventional Cas effector proteins (bars) and respective guide RNA length (green line) (nt). The V-F type nucleases are highlighted in the gray area, AsCas12f1 protein is highlighted in the red bar. b Structure of the AsCas12f1 WT gRNA consisting of tracrRNA and crRNA. c T4AT6/GGG schemes for gRNA engineering are indicated in schematic diagram. T4AT6, TTTTATTTTTT. d The indel frequencies of AsCas12f1 usingT4AT6/GGG engineered gRNAs at four different target sites in HEK293T cells. Values and error bars represent mean and s.d. (n = 3). e MS scheme for gRNA engineering is indicated in schematic diagram. MS, modify site throughout the tracrRNA and crRNA. f The indel frequencies of AsCas12f1 using MS engineered gRNA at four different target sites in HEK293T cells. Values and error bars represent mean and s.d. (n = 3). g DS schemes for gRNA engineering are indicated in schematic diagram. DS, delete site of tracRNA. h The indel frequencies of AsCas12f1 using DS engineered gRNA at four different target sites in HEK293T cells. Values and error bars represent mean and s.d. (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001
Engineered AsCas12f1 gRNA augments editing frequency. a The comparison between AsCas12f1 WT and As-v1 gRNA. The MS is marked in yellow and the T4AT6 is marked in grey. b Indel activities of the different modifications of sgRNA with wild-type AsCas12f1 sgRNA (relative to WT) on 13 genomic loci in HEK293T cells. FC, fold change. c Comparison of indel editing efficiencies of UnCas12f1 and engineered AsCas12f1 at 12 genomic sites in HEK293T cells. Values and error bars represent mean and s.d. (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001. d Workflow for genome editing in mouse zygotes or to obtain F0 mice. e Average frequencies of indels at six target sites using AsCas12f1 in mouse blastocysts. Values and error bars represent mean and s.d. (n = 4)
Engineered AsCas12f1 system enables robust and faithful gene editing in mouse embryos
To evaluate the feasibility and efficiency of the engineered CRISPR-AsCas12f1 system, we tested six target sites from five different genes (Dmd [29], Dctn6 [30], Foxp1 [31], Polg [32], and Tyr [33]) in mouse embryos. Genome editing was conducted in mouse zygotes using microinjection of AsCas12f1-encoding mRNA and the appropriate sgRNA as previously reported [33]. The mouse zygotes were cultured in vitro to blastocysts after injection and then genotyped (Fig. 2d). Notably, all six target sites showed efficient editing with an average efficiency ranging from 17.7 to 62.5% (Fig. 2e; Table S5).
Generation of Tyr mutant mice using engineered AsCas12f1 system
Then we further attempted to examine the practicality of AsCas12f1 on animal disease models. We generated Tyr mutant mice to simulate human oculocutaneous albinism (OCA) (Fig. 3a). The Tyr mutation is the main cause of OCA, which is characterized by the reduction or absence of melanin in skin, hair, and eyes [34]. After microinjection, we transferred zygotes into surrogate mice. Of the four pups obtained, three contained the expected editing outcomes at the Tyr site, with efficiency ranging from 38.6 to 49.7% (Fig. 3b, c). In comparison with the wild-type (WT) mice, they showed heterozygous phenotypes with grey complexion (Fig. 3b). Histological H&E staining further confirmed the local or complete absence of melanin in the skin (Fig. 3d). In addition, deep sequencing revealed that the average frequency of off-target editing in the mutant mice remained low (< 1%) at possible off-target sites (POTs) (Fig. 3e). Since white Tyr mutant mice were not available in the F0 generation, we intercrossed the heterozygotes and successfully obtained white mice in the F1 generation (Fig. 3c). All data demonstrated that the mouse model represented the symptoms of the human OCA disease, proving the effectiveness of the AsCas12f1 system in gene editing and mouse model construction.
Engineered AsCas12f1 system can induce Tyr mutant mice. a The target sequence at the Tyr locus. Target sequence (blue), PAM region (red). The red arrows highlight the cleavage site. b Alignments of mutant sequences from targeted deep sequencing. Target sequence (blue), PAM region (green), and indels (red). The column on the right indicates the frequencies of mutant alleles. c Photographs of F0 and F1 generation mice generated by engineered AsCas12f1 system. In the F0 generation, three of them showed heterozygous phenotypes with grey complexion. d H&E staining of abdominal skin from WT and mutant mice at 100x, 200x, and 400x, respectively. The red arrows highlight the melanin in the basal layer of the epidermis. Scale bars: 100 μm /50 μm/20 μm. H&E, hematoxylin and eosin; WT, wild type. e The potential off-target sites (POTs) in Tyr mutant mice were detected by Hi-TOM analysis. All the POTs and primer sequences for the off-target assay are listed in Table S3 and S4
Generation of Dmd and Foxp1 mutant mice using the engineered AsCas12f1 system
In addition, we also attempted to mimic the Duchenne muscular dystrophy (Dmd) gene and ***Fork-head Box P subfamily 1 (Foxp1) gene mutant mice (Fig. 4). Duchenne muscular dystrophy is caused by mutations in the Dmd gene, which encodes dystrophin protein. These mutations cause frameshift and/or premature stop codon formation in the Dmd gene, thus disrupting the expression of dystrophin and leading to the development of Dmd [29, 35]. Deep sequencing results showed that 34.3% indels occurred at Dmd loci in the F0 generation (Fig. 4b). The Dmd mutant mice and control littermates were weighed every 2 weeks, and the data showed that both the female and male mutant mice were significantly lighter than their control littermates (Fig. 4c, d). As shown in Fig. 4e, the Dmd mutant mouse displayed typical muscular dystrophy signs, as evidenced by increased fiber size variation.
Engineered AsCas12f1 system can induce Dmd and Foxp1 mutant mice. a The target sequence at the Dmd locus. Target sequence (blue), PAM region (red). The red arrows highlight the cleavage site. b Alignments of mutant sequences from targeted deep sequencing. Target sequence (blue), PAM region (green), and indels (red). The column on the right indicates the frequencies of mutant alleles. c Body mass comparison of male Dmd mutant and WT (n = 3). d Body mass comparison of female Dmd mutant and WT (n = 3). e H&E staining of gastrocnemius from WT and mutant mice at 200x. Dmd mutant mice displayed myopathy with excessive fiber size variation. f The target sequence at the Dmd locus. Target sequence (blue), PAM region (red). The red arrows highlight the cleavage site. g H&E staining of hippocampus from WT and mutant mice. (200× and 400×). Foxp1 mutant mice displayed significant nuclear pyknosis (black arrows). h Travel path of wild-type mice and Foxp1 mutant mice in the open field. Foxp1 mutant mice displayed a higher activity level within the open field than WT mice. i Latency to feed of the mice in the novelty-suppressed feeding assay. Foxp1 mutant mice displayed a lower activity level within the novelty-suppressed feeding than WT mice
Fork-head Box P subfamily 1 (Foxp1) has been linked to neurodevelopmental disorders, suggesting that it may play a central role in various cognitive and social processes [36, 37]. Foxp1-specific deletions and mutations have been reported in patients with intellectual disability (ID), autism spectrum disorder (ASD), speech and language deficits [31, 37]. We generated Foxp1 mutant mice to simulate human Foxp1 mutations (Fig. 4f). The target deep sequencing results showed that the efficiency ranged from 26.9 to 37.8% (Fig. S4a). The Foxp1 mutant mice were smaller in size compared with their WT littermates (Fig. S4b). Moreover, histological H&E staining revealed a large number of nuclear pyknosis in Foxp1 mutant hippocampus (Fig. 4g). Due to hippocampal damage, short-term memory is impaired in Foxp1 mutant mice. For both distances traveled and total rearing time, Foxp1 mutant mice displayed a higher activity level within the open field than wild-type mice (Fig. 4h). In the novelty-suppressed feeding assay, the latency of each mouse to approach and eat a new food was used as an index of anxiety-like behavior with longer latency indicating anxiety [38, 39]. As shown in Fig. 4i, the latency to feeding increased sharply in Foxp1 mutant mice. It revealed that Foxp1 mutant mice displayed significantly lower anxiety. Furthermore, no mutations were detected at the potential off-target sites in Dmd and Foxp1 mutant mice (Fig. S5a and b), indicating the efficiency and precision of AsCas12f1 system. In conclusion, we validated the feasibility of the CRISPR-AsCas12f1 system in mammals and successfully constructed multiple mouse disease models for therapy.
Discussion
In this study, we engineered a sgRNA variant for CRISPR-AsCas12f1 system, which can induce genome editing 3.17-fold more efficiently than wild-type sgRNA in mammalian cells. In addition, we confirmed that the engineered AsCas12f1 system showed the feasibility and efficiency in Tyr/Dmd/Foxp1/Polg mutant mouse embryos. Notably, this strategy can be used to generate Tyr/Dmd/Foxp1 mutant mouse disease models in the F0 generation. These results demonstrated that a higher efficiency could be achieved by the engineered AsCas12f1 system in cells and mice.
Cas12f1 has an extra-long gRNA for its compact protein size, which may be associated with Cas12f1’s ssDNA cleavage activity [7]. Through the analysis of sgRNA engineering strategies, we found that some regions do not directly interact with effector proteins. In addition, we tried to truncate parts of original sgRNA to improve dsDNA cleavage activity. It is interesting that our MS approach was in line with recent studies [13, 14], in that the trimmed regions are structurally disordered. One interpretation would be that the flexibility of disordered region might hinder AsCas12f1 homodimerization [7]. Moreover, all DS modifications of stem 2 region resulted in significant decrease in indels, indicating that stem 2 is a major contributor to sgRNA–protein interactions. The T4AT6 method may obviate the termination signal for the U6 promoter and enhance the compatibility between the gRNA and AsCas12f1, thereby improving the editing efficiency [7, 40]. Together, these may be the reasons for the efficiency improvement of our engineered AsCas12f1 system.
Although our engineered AsCas12f1 system has induced stable gene editing in cells and mouse embryos, we observed its editing efficiency could be further improved. Despite of sgRNA engineering, genome editing efficiency can also be improved by structural analysis and protein engineering [4, 13, 14, 41]. With the assistance of structural information, protein residues near the nucleic acid were replaced to introduce more interactions or promote conformational flexibility [13, 41]. The variants with enhanced activity of AsCas12f1 were then further increased by combining beneficial mutations in previous studies, such as AsCas12f1-YHAM (F48Y/S188H/V232A/E316M) [13], AsCas12f-HKRA (I123H/D195K/D208R/V232A) [13], enAsCas12f1 (D196K/N199K/G276R/N328G/D364R) [14], and AsCas12f1-v5.1 (N70Q / K103R /A104R /S118A /D364R) [41]. Although these protein engineering schemes have significantly improved the activity of AsCas12f1 protein [13, 14, 41], different engineering strategies and screening methods could result in different effective mutation combinations. Therefore, the optimal combination of AsCas12f1 protein mutations needs to be verified in the future.
Notably, we successfully generated three mouse mutant models, fully demonstrating the feasibility and stability of the engineered AsCas12f1 system in mice. In comparison with adeno-associated virus (AAV)-based gene delivery [13, 42], our animal models were obtained by microinjection and embryo transfer. The microinjection process, typically visualized under a microscope, allows for real-time monitoring of delivery success.
Taken together, we converted AsCas12f1 into an efficient genome editor by gRNA engineering. This study develops a novel theoretical reference for the engineering modification of CRISPR system, and provides a compact gene editing tool for basic research with remarkable promise for therapeutic applications.
Data availability
The authors state that all data necessary for confirming the conclusions presented in this article are represented fully within the article. The datasets generated and/or analyzed during the current study are available from the author upon reasonable request.
References
Stella S, Alcón P, Montoya G (2017) Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss army knives of genome editing. Nat Struct Mol Biol 24:882–892
Xin C, Yin J, Yuan S et al (2022) Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption. Nat Commun 13:5623
Harrington LB, Burstein D, Chen JS et al (2018) Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science 362:839–842
Xu X, Chemparathy A, Zeng L et al (2021) Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing. Mol Cell 81:4333-4345.e4
Wu Z, Zhang Y, Yu H et al (2021) Programmed genome editing by a miniature CRISPR-Cas12f nuclease. Nat Chem Biol 17:1132–1138
Kong X, Zhang H, Li G et al (2023) Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing. Nat Commun 14:2046
Kim DY, Lee JM, Moon SB et al (2022) Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus. Nat Biotechnol 40:94–102
Wang Y, Wang Y, Pan D et al (2022) Guide RNA engineering enables efficient CRISPR editing with a miniature Syntrophomonas palmitatica Cas12f1 nuclease. Cell Rep 40:111418
Hsu PD, Scott DA, Weinstein JA et al (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31:827–832
Kempton HR, Goudy LE, Love KS, Qi LS (2020) Multiple input sensing and signal integration using a split Cas12a system. Mol Cell 78:184-191.e3
Takeda SN, Nakagawa R, Okazaki S et al (2021) Structure of the miniature type V-F CRISPR-Cas effector enzyme. Mol Cell 81:558-570.e3
Bigelyte G, Young JK, Karvelis T et al (2021) Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells. Nat Commun 12:6191
Hino T, Omura SN, Nakagawa R et al (2023) An AsCas12f-based compact genome-editing tool derived by deep mutational scanning and structural analysis. Cell 186:4920-4935.e23
Wu T, Liu C, Zou S et al (2023) An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity. Nat Chem Biol 19:1384
Qian Y, Zhao D, Sui T et al (2021) Efficient and precise generation of Tay-Sachs disease model in rabbit by prime editing system. Cell Discov 7:50
Sui T, Song Y, Liu Z et al (2018) CRISPR-induced exon skipping is dependent on premature termination codon mutations. Genome Biol 19:164
Chen S, Liu Z, Xie W, Yu H, Lai L, Li Z (2022) Compact Cje3Cas9 for efficient in vivo genome editing and adenine base editing. CRISPR J 5:472–486
Zhao D, Qian Y, Li J, Li Z, Lai L (2022) Highly efficient A-to-G base editing by ABE8.17 in rabbits. Mol Ther Nucleic Acids 27:1156–1163
Qian Y, Wang D, Niu W et al (2023) Development of a highly efficient prime editor system in mice and rabbits. Cell Mol Life Sci 80:346
Walz N, Mühlberger A, Pauli P (2016) A human open field test reveals Thigmotaxis related to agoraphobic fear. Biol Psychiatry 80:390–397
Zeng J, Meng X, Zhou P et al (2019) Interferon-α exacerbates neuropsychiatric phenotypes in lupus-prone mice. Arthritis Res Ther 21:205
Bae S, Park J, Kim J-S (2014) Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30:1473–1475
Liu Q, Wang C, Jiao X et al (2019) Hi-TOM: a platform for high-throughput tracking of mutations induced by CRISPR/Cas systems. Sci China Life Sci 62:1–7
Huang TP, Newby GA, Liu DR (2021) Precision genome editing using cytosine and adenine base editors in mammalian cells. Nat Protoc 16:1089–1128
Sasnauskas G, Tamulaitiene G, Druteika G et al (2023) TnpB structure reveals minimal functional core of Cas12 nuclease family. Nature 616:384–389
Xiang G, Li Y, Sun J et al (2023) Evolutionary mining and functional characterization of TnpB nucleases identify efficient miniature genome editors. Nat Biotechnol. https://doi.org/10.1038/s41587-023-01857-x
Kleinstiver BP, Sousa AA, Walton RT et al (2019) Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol 37:276–282
Bin Moon S, Lee JM, Kang JG et al (2018) Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3’-overhang. Nat Commun 9:3651
Nelson CE, Wu Y, Gemberling MP et al (2019) Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med 25:427–432
Liu G, Lin Q, Jin S, Gao C (2022) The CRISPR-Cas toolbox and gene editing technologies. Mol Cell 82:333–347
Rousso DL, Pearson CA, Gaber ZB et al (2012) Foxp-mediated suppression of N-cadherin regulates neuroepithelial character and progenitor maintenance in the CNS. Neuron 74:314–330
Rahman S, Copeland WC (2019) POLG-related disorders and their neurological manifestations. Nat Rev Neurol 15:40–52
Liu Z, Chen S, Xie W et al (2022) Versatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9. Mol Ther 30:256–267
Ghodsinejad Kalahroudi V, Kamalidehghan B, Arasteh Kani A et al (2014) Two novel tyrosinase (TYR) gene mutations with pathogenic impact on oculocutaneous albinism type 1 (OCA1). PLoS ONE 9:e106656
Olson EN (2021) Toward the correction of muscular dystrophy by gene editing. Proc Natl Acad Sci U S A 118:e2004840117
Hamdan FF, Daoud H, Rochefort D et al (2010) De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. Am J Hum Genet 87:671–678
Bacon C, Schneider M, Le Magueresse C et al (2015) Brain-specific Foxp1 deletion impairs neuronal development and causes autistic-like behaviour. Mol Psychiatry 20:632–639
Ramaker MJ, Dulawa SC (2017) Identifying fast-onset antidepressants using rodent models. Mol Psychiatry 22:656–665
Rosso M, Wirz R, Loretan AV et al (2022) Reliability of common mouse behavioural tests of anxiety: a systematic review and meta-analysis on the effects of anxiolytics. Neurosci Biobehav Rev 143:104928
Lee HJ, Kim HJ, Lee SJ (2023) Miniature CRISPR-Cas12f1-mediated single-nucleotide microbial genome editing using 3’-truncated sgRNA. CRISPR J 6:52–61
Wu Z, Liu D, Pan D et al (2023) Structure and engineering of miniature Acidibacillus sulfuroxidans Cas12f1. Nat Catal 6:695–709
Wang D, Zhang F, Gao G (2020) CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181:136–150
Acknowledgements
The authors thank Peiran Hu and Nannan Li for assistance at the Embryo Engineering Center for the critical technical assistance.
Funding
This study was financially supported by the National Natural Science Foundation of China (Grant no. 32101226), the Young Elite Scientist Sponsorship Program by CAST (No. YESS 20210189). The workflow in the manuscript was drawn in Figdraw.
Author information
Authors and Affiliations
Contributions
PF, LL, and TS. conceived and designed the experiments. PF and HW performed the experiments. FZ, TZ, JL, and XS analyzed the data. YY and HX contributed reagents/materials/analysis tools. P.F. and H.W. wrote the paper. All authors have read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing or financial interests.
Consent for publication
All authors read and approved the final manuscript.
Ethical approval
All mice were obtained from the Laboratory Animal Center of Jilin University (Changchun, China). All procedures using mice were approved by the Institutional Animal Care and Use Committee of Jilin University (IACUC number: SY202302001).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Fan, P., Wang, H., Zhao, F. et al. Targeted mutagenesis in mice via an engineered AsCas12f1 system. Cell. Mol. Life Sci. 81, 63 (2024). https://doi.org/10.1007/s00018-023-05100-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00018-023-05100-3